2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the…
Share your thoughts on lumbar punctures in Parkinson’s research
Cure Parkinson’s is conducting a new online survey to explore patient perspectives on the use of lumbar punctures in Parkinson’s research and clinical trials. Developed in collaboration with the Centre for Preventative Neurology and Queen Mary University and alongside people with Parkinson’s, we hope to…
Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks…
Parkinson’s and dementia: improving cognitive measures to enable better treatments
Recently, several international Parkinson’s and Dementia with Lewy Bodies (DLB) advocacy organizations, including Cure Parkinson’s, held a roundtable to discuss the development of better tools for measuring cognitive changes in people with Parkinson’s and DLB.
Our two newest pre-clinical research projects
Cure Parkinson’s is pleased to announce the funding for two new projects as part of our annual iLCT Pipeline Research Acceleration Grant Programme.